var data={"title":"Opsoclonus myoclonus syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Opsoclonus myoclonus syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/contributors\" class=\"contributor contributor_credentials\">Josep Dalmau, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/contributors\" class=\"contributor contributor_credentials\">Myrna R Rosenfeld, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/contributors\" class=\"contributor contributor_credentials\">Lisa M DeAngelis, MD, FAAN, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H24048016\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opsoclonus-myoclonus syndrome (OMS), also known as opsoclonus myoclonus ataxia, is a syndrome that includes opsoclonus along with diffuse or focal body myoclonus and truncal titubation with or without ataxia and other cerebellar signs.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Opsoclonus is a disorder of ocular motility characterized by spontaneous, arrhythmic, conjugate saccades occurring in all directions of gaze without a saccadic interval.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myoclonus is a clinical sign that is characterized by brief, shock-like, involuntary movements caused by muscular contractions or inhibitions.</p><p/><p>Patients with OMS are sometimes described as having dancing eyes and feet. Although OMA can be paraneoplastic in origin, it can also result from viral infections, post-streptococcal pharyngitis, metabolic disorders, metastases, and intracranial hemorrhage [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>This topic discusses opsoclonus myoclonus ataxia. An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. Other disorders causing myoclonus are also discussed separately. (See <a href=\"topic.htm?path=overview-of-paraneoplastic-syndromes-of-the-nervous-system\" class=\"medical medical_review\">&quot;Overview of paraneoplastic syndromes of the nervous system&quot;</a> and <a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-peripheral-nerve-and-muscle\" class=\"medical medical_review\">&quot;Paraneoplastic syndromes affecting peripheral nerve and muscle&quot;</a> and <a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-the-spinal-cord-and-dorsal-root-ganglia\" class=\"medical medical_review\">&quot;Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia&quot;</a> and <a href=\"topic.htm?path=classification-and-evaluation-of-myoclonus\" class=\"medical medical_review\">&quot;Classification and evaluation of myoclonus&quot;</a> and <a href=\"topic.htm?path=symptomatic-secondary-myoclonus\" class=\"medical medical_review\">&quot;Symptomatic (secondary) myoclonus&quot;</a> and <a href=\"topic.htm?path=treatment-of-myoclonus\" class=\"medical medical_review\">&quot;Treatment of myoclonus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H24047689\"><span class=\"h1\">PEDIATRIC SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opsoclonus-myoclonus syndrome (OMS) is rare; one prospective study in the United Kingdom estimated an incidence of 0.18 cases per million per year [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3\" class=\"abstract_t\">3</a>]. OMS affects mainly young children with a mean age of 1.5 to 2 years [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3-5\" class=\"abstract_t\">3-5</a>]. Some series, but not others, have found a higher prevalence in girls. A female predominance is characteristic of most, but not all, autoimmune disorders [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/6\" class=\"abstract_t\">6</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H24048187\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autoimmunity is believed to underlie paraneoplastic and non-paraneoplastic OMS in children. One study demonstrated B and T-cell recruitment in the cerebrospinal fluid (CSF) in association with neurologic signs in pediatric opsoclonus-myoclonus syndrome [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/7\" class=\"abstract_t\">7</a>]. The CSF findings correlated with relapses and disease progression. A pathologic study demonstrated that affected children both with and without neuroblastoma have a high incidence of antibodies that react with CNS antigens, some of which are directed against cerebellar Purkinje cells [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/8\" class=\"abstract_t\">8</a>]. Other studies have shown that the sera of children with OMS demonstrate antibodies against the surface of cerebellar granular neurons; these antibodies also have an antiproliferative and cytotoxic effect on neuroblastoma cells [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/9,10\" class=\"abstract_t\">9,10</a>]. The identity of the autoantigen(s) remains unknown. One report indicates that the chemokine&nbsp;receptor ligand CCL21 is elevated in patients with pediatric OMA and returns to control levels when they are treated with corticosteroids or&nbsp;ACTH, but not other immunosuppressive&nbsp;agents [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/11\" class=\"abstract_t\">11</a>]. CCL21 is a ligand for CCL7, a receptor balancing tolerance and immune response. The CCL21 level&nbsp;is&nbsp;positively correlated with the severity and duration of the neurological abnormality. These findings require further study and validation.</p><p>A genetic susceptibility for OMS is suggested by the results of one study that found that the parents of children with OMS were more likely to have autoimmune disease and autoantibodies compared with the parents of healthy controls (16 versus 2 percent, 43 versus 8 percent, respectively) [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/12\" class=\"abstract_t\">12</a>]. However, in one large case series of 105 children, none of the several twin siblings in the cohort were affected [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4\" class=\"abstract_t\">4</a>].</p><p>The most common malignancy associated with OMS in children is neuroblastoma. Almost 50 percent of children with OMS have an underlying neuroblastoma, and in turn, about 2 percent of children with neuroblastoma develop paraneoplastic OMA [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/13,14\" class=\"abstract_t\">13,14</a>]. While neuroblastoma is somewhat more common among boys than girls, the associated OMS is more common in girls [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-neuroblastoma\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of neuroblastoma&quot;</a>.)</p><p>Non-paraneoplastic OMS in children is believed to have a parainfectious origin in some cases. Implicated pathogens include hepatitis C [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/16\" class=\"abstract_t\">16</a>], Lyme disease [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/17\" class=\"abstract_t\">17</a>], Epstein-Barr virus [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/18,19\" class=\"abstract_t\">18,19</a>], post-streptococcal infection [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/2\" class=\"abstract_t\">2</a>], HIV (possibly with immune reconstitution inflammatory syndrome) [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/20\" class=\"abstract_t\">20</a>], Coxsackie B3 [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/21\" class=\"abstract_t\">21</a>], mycoplasma pneumoniae [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/22\" class=\"abstract_t\">22</a>], and rotavirus [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3\" class=\"abstract_t\">3</a>]. In idiopathic cases of OMS, a post-viral origin is sometimes inferred based upon a suggestive history of a viral prodrome [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. One case of OMS has been reported in the setting of celiac disease (an in immune-mediated inflammatory disorder of the small intestine) [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H24048201\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with OMS usually present with a subacute onset of ataxia and falls, progressing over days to weeks [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4,24,25\" class=\"abstract_t\">4,24,25</a>]. A viral prodrome is common, but in one series was similarly prevalent in patients with paraneoplastic and non-paraneoplastic OMS [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. Myoclonus of the limbs and trunk, tremor, and hypotonia often develop subsequently. Behavioral changes (often described as irritability) and moderate to severe sleep disturbances are common.</p><p>Most patients also have opsoclonus: spontaneous, involuntary, arrhythmic, conjugate, multi-directional saccades occurring in all directions of gaze without a saccadic interval. Opsoclonus may not be present at initial evaluation [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3\" class=\"abstract_t\">3</a>]. The absence of this most distinctive finding can delay diagnosis of OMS, particularly if the patient does not have a known neuroblastoma.</p><p>Symptoms precede the diagnosis of neuroblastoma in about one-half of patients. Symptoms usually fluctuate in severity and may have a prolonged course.</p><p class=\"headingAnchor\" id=\"H24048209\"><span class=\"h2\">Evaluation</span></p><p class=\"headingAnchor\" id=\"H6266249\"><span class=\"h3\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Myoclonus, encephalopathy, ataxia, and less commonly, opsoclonus may be features of toxic-metabolic encephalopathy, particularly hyperosmolar coma, liver disease, and intoxications [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/26,27\" class=\"abstract_t\">26,27</a>]. Structural disease (eg, metastasis, inflammation, demyelination, hemorrhage, sarcoidosis) within the pons <span class=\"nowrap\">and/or</span> cerebellum has also been reported to produce some of the neurologic deficits of OMS. Some cases of OMS have been initially misdiagnosed as acute cerebellar ataxia [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=acute-cerebellar-ataxia-in-children\" class=\"medical medical_review\">&quot;Acute cerebellar ataxia in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6266312\"><span class=\"h3\">Testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no laboratory or other test that confirms the diagnosis of OMS, which is a clinical diagnosis. No specific paraneoplastic biomarkers have been identified for OMS associated with neuroblastoma. While children with paraneoplastic OMS have a higher frequency of other paraneoplastic antibodies (including anti-Hu antibodies) than healthy controls, the sensitivity and specificity is low, and autoantibody screening in this population is not routine [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3,14,29\" class=\"abstract_t\">3,14,29</a>].</p><p>All children presenting with OMS must be evaluated for neuroblastoma [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/15\" class=\"abstract_t\">15</a>]. A screening protocol includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest, abdominal, and pelvic MRI</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Measurement of urinary vanillylmandelic acid (VMA) and homovanillic (HVA)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>123-I-metaiodobenzylguanidine (MIBG) scan if MRI results are unrevealing</p><p/><p>When negative, the evaluation should be repeated after several months [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/30\" class=\"abstract_t\">30</a>]. The evaluation of children with possible neuroblastoma is discussed in detail separately. (See <a href=\"topic.htm?path=clinical-presentation-diagnosis-and-staging-evaluation-of-neuroblastoma\" class=\"medical medical_review\">&quot;Clinical presentation, diagnosis, and staging evaluation of neuroblastoma&quot;</a>.)</p><p>In children without neuroblastoma, brain imaging (MRI with gadolinium) is recommended to rule out structural lesions; this study is usually normal in patients with OMS [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3,26\" class=\"abstract_t\">3,26</a>]. Laboratory testing and review of medications should be performed to exclude a toxic-metabolic encephalopathy, in particular, hyperosmolar coma, liver disease, and intoxications. (See <a href=\"topic.htm?path=acute-toxic-metabolic-encephalopathy-in-children#H8\" class=\"medical medical_review\">&quot;Acute toxic-metabolic encephalopathy in children&quot;, section on 'Diagnostic approach'</a>.) If these are negative, evaluation for viral infections is reasonable, including testing for human immunodeficiency virus (HIV) infection [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/20\" class=\"abstract_t\">20</a>]. Cerebrospinal fluid analysis should be obtained if there is concern for acute central nervous system infection; this is typically normal in cases of OMA but may reveal a lymphocytic pleocytosis. EEG in cases of OMA has also been reported to be normal [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H24048217\"><span class=\"h2\">Treatment and prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no controlled studies of treatment in pediatric OMS. Removal of the neuroblastoma, when present, does not appear to improve neurologic symptoms [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4,31,32\" class=\"abstract_t\">4,31,32</a>]. The treatment of neuroblastoma is discussed separately. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-neuroblastoma\" class=\"medical medical_review\">&quot;Treatment and prognosis of neuroblastoma&quot;</a>.)</p><p>Observational studies suggest that OMS in children may respond to immunologic treatment (eg, glucocorticoids, ACTH, plasma exchange, intravenous immunoglobulin, immuran, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil) often used in combinations [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4,33-38\" class=\"abstract_t\">4,33-38</a>]. Examples of treatment regimens include <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 2 <span class=\"nowrap\">mg/kg</span> per day with a prolonged taper over several months and pulsed <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> therapy using 20 <span class=\"nowrap\">mg/m2</span> for three days, given monthly [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/25,39\" class=\"abstract_t\">25,39</a>]. One protocol describes using ACTH for 40 weeks, beginning with 75 <span class=\"nowrap\">IU/m2</span> twice a day for one week and subsequent tapers based upon clinical response [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/40\" class=\"abstract_t\">40</a>]. <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab</a> added to other immunotherapies has been reported effective in small case series [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/40-42\" class=\"abstract_t\">40-42</a>].</p><p>In one nonrandomized comparison of immunotherapies, blinded rater assessments suggested that corticotropin therapy was more efficacious than glucocorticoid therapy and that combination therapies (corticotropin with <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>) appeared to be more effective than corticotropin alone, although also associated with a higher rate of complications [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/43\" class=\"abstract_t\">43</a>]. Multi-center clinical trials of immunotherapies in pediatric OMS are in progress [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/24,26\" class=\"abstract_t\">24,26</a>].</p><p>The neurologic prognosis is guarded. Among different case series, motor symptoms appear to improve or resolve in approximately 60 percent during initial treatment [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/5,33,35\" class=\"abstract_t\">5,33,35</a>]. Neurologic relapses may occur during steroid withdrawal or with intercurrent infections requiring prolonged treatment in some cases [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4,36\" class=\"abstract_t\">4,36</a>]. However, regardless of pathogenesis, approximately 60 to 80 percent of patients have residual behavioral abnormalities or psychomotor retardation that sometimes become increasingly problematic later in life [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4,5,33,37,44-46\" class=\"abstract_t\">4,5,33,37,44-46</a>]. Early and more intensive treatment does not clearly improve neuropsychiatric disability, which can occur even while motor symptoms have resolved [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/45,47\" class=\"abstract_t\">45,47</a>]. Sleep problems and associated rage attacks may respond to <a href=\"topic.htm?path=trazodone-drug-information\" class=\"drug drug_general\">trazodone</a> [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/48\" class=\"abstract_t\">48</a>].</p><p>Tumors in children with paraneoplastic OMS appear to have a better prognosis than tumors in patients without paraneoplastic symptoms [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H24047696\"><span class=\"h1\">ADULT SYNDROME</span></p><p class=\"headingAnchor\" id=\"H6361449\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opsoclonus-myoclonus syndrome (OMS) in adults may be paraneoplastic or idiopathic in origin. An underlying cancer is found in approximately 20 to 40 percent of cases [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/1,49-51\" class=\"abstract_t\">1,49-51</a>]. Patients with idiopathic OMS tend to be younger than patients with paraneoplastic OMS (mean age 40 versus 55 years) [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,51\" class=\"abstract_t\">49,51</a>]. An exception is patients with ovarian teratoma, who often present before age 30 years [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/51\" class=\"abstract_t\">51</a>].</p><p>The most frequent tumor associated with OM in adults is small cell lung cancer (SCLC) [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/51,52\" class=\"abstract_t\">51,52</a>]. Other tumors have been reported, including non-small cell lung cancer, breast cancer, ovarian teratoma and other gynecologic cancers, gastric adenocarcinoma, malignant melanoma, and bladder cancer [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,51,53-59\" class=\"abstract_t\">49,51,53-59</a>].</p><p>Most cases of paraneoplastic OMS in adults are not associated with well characterized antibodies [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/51\" class=\"abstract_t\">51</a>]. An exception is a small subgroup of women with OMA who have of anti-Ri (antineuronal nuclear autoantibody type 2, or ANNA-2) antibodies, usually in association with breast cancer (sometimes gynecologic, lung, or bladder cancers) [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,53,54,60-62\" class=\"abstract_t\">49,53,54,60-62</a>]. The target antigens of anti-Ri antibodies are the Nova proteins that play a role in the regulation of synaptic proteins [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/54,63\" class=\"abstract_t\">54,63</a>]. A few patients with paraneoplastic OMS have had anti-Hu or other paraneoplastic antibodies; in such cases, these are probably nonspecific markers of underlying cancers rather than linked to OMS [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,52\" class=\"abstract_t\">49,52</a>].</p><p>Antibodies to neuronal surface antigens have also been reported in association with OMS, including a small number of patients with antibodies to N-methyl-D-aspartate receptor (NMDAR), gamma-aminobutyric acid type A (GABA-A) and GABA-B receptors, dipeptidyl-peptidase-like protein-6 (DPPX), and human natural killer 1 (HNK-1), a novel epitope contained within myelin-associated glycoprotein (MAG) as well as several other brain proteins [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/51,64,65\" class=\"abstract_t\">51,64,65</a>]. Antibodies to the glycine receptor (GlyR) have been found in up to 20 percent of patients with lung cancer and OMS but do not appear to be sensitive or specific for the disorder [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/51\" class=\"abstract_t\">51</a>]. </p><p>Non-paraneoplastic OMS has been reported in adults in association with various infections, including Lyme disease [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/66\" class=\"abstract_t\">66</a>], enterovirus [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/67\" class=\"abstract_t\">67</a>], West Nile virus [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/68\" class=\"abstract_t\">68</a>], Epstein Barr virus [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/69\" class=\"abstract_t\">69</a>], HIV [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/70-72\" class=\"abstract_t\">70-72</a>], salmonella [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/73\" class=\"abstract_t\">73</a>], cytomegalovirus [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/74\" class=\"abstract_t\">74</a>], after anti-Rubella vaccination [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/75\" class=\"abstract_t\">75</a>], and post-streptococcal infection [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/76\" class=\"abstract_t\">76</a>]. Many cases of non-paraneoplastic OMS are idiopathic and often assumed to be parainfectious in origin [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49\" class=\"abstract_t\">49</a>].</p><p class=\"headingAnchor\" id=\"H6361456\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In adults, paraneoplastic OMS often develops with truncal ataxia, resulting in gait difficulty and frequent falls [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,50,77\" class=\"abstract_t\">49,50,77</a>]. Most patients have both myoclonus and opsoclonus on presentation; some complain of nausea <span class=\"nowrap\">and/or</span> vomiting. Limb ataxia, tremor, and dysarthria are less frequently present. Symptoms progress rapidly, leading to substantive disability within weeks. Brainstem and cerebellar signs may also be present [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/53,77\" class=\"abstract_t\">53,77</a>]. Encephalopathy accompanies ocular and motor signs in 30 to 60 percent of patients with paraneoplastic OMS and is a less frequent finding in non-paraneoplastic OMS (10 percent) [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,51,77\" class=\"abstract_t\">49,51,77</a>]. In patients with anti-Ri antibodies, opsoclonus is a frequent but not invariable finding.</p><p class=\"headingAnchor\" id=\"H6361463\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>OMS should be distinguished from other disorders which can cause similar neurologic symptoms. (See <a href=\"#H6266249\" class=\"local\">'Differential diagnosis'</a> above.):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brain imaging (MRI with gadolinium) is recommended to rule out structural lesions that can produce symptoms that may be similar to OMA [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/26\" class=\"abstract_t\">26</a>]. This is usually normal in OMS, but occasionally shows hyperintensity in the dorsal pons or midbrain on T2-weighted images [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/78\" class=\"abstract_t\">78</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory testing and review of medications should be performed to exclude a toxic-metabolic encephalopathy particularly hyperosmolar coma, liver disease, and intoxications. (See <a href=\"topic.htm?path=acute-toxic-metabolic-encephalopathy-in-adults#H11070685\" class=\"medical medical_review\">&quot;Acute toxic-metabolic encephalopathy in adults&quot;, section on 'Diagnosis'</a>.)</p><p/><p>Cerebrospinal fluid should be obtained if there is concern for acute central nervous system infection; in OMS this may be normal or show mild elevations of protein or mild lymphocytic pleocytosis [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,77\" class=\"abstract_t\">49,77</a>].</p><p>Patients with OMS who are over the age of 50 years and those with associated encephalopathy should be rigorously assessed for occult malignancy [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/1\" class=\"abstract_t\">1</a>] (see <a href=\"topic.htm?path=overview-of-paraneoplastic-syndromes-of-the-nervous-system#H13\" class=\"medical medical_review\">&quot;Overview of paraneoplastic syndromes of the nervous system&quot;, section on 'Occult malignancy'</a>). One study identified a subset of young women (ages 15 to 32 years) who developed OMS in association with systemic teratoma; no autoantibodies were identified, and 74 percent had a full recovery after tumor removal and immunotherapy [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/79\" class=\"abstract_t\">79</a>].</p><p>While it is reasonable to test for paraneoplastic biomarkers, most adult patients with paraneoplastic OMS will not test positive [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,80\" class=\"abstract_t\">49,80</a>].</p><p>Testing for human immunodeficiency virus (HIV) should be performed if risk factors are present, as OMS can be the initial manifestation of HIV infection or may occur during immune reconstitution at the onset of antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/70-72\" class=\"abstract_t\">70-72</a>].</p><p class=\"headingAnchor\" id=\"H6361600\"><span class=\"h2\">Treatment and prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some adults with paraneoplastic OMS have resolution of neurologic symptoms with treatment of the underlying neoplasm [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49,59\" class=\"abstract_t\">49,59</a>].</p><p>Adults may be less likely to respond to immunotherapy compared with children. Nonetheless, in uncontrolled observations, clinical responses have been reported with corticosteroids, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, and intravenous immunoglobulin. In two cases, patients responded to treatment with high doses of <a href=\"topic.htm?path=clonazepam-drug-information\" class=\"drug drug_general\">clonazepam</a> (8 to 12 mg daily) after no response to immunotherapy [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/81\" class=\"abstract_t\">81</a>]. Another case report describes a therapeutic response to <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a> in a patient with OMS [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/82\" class=\"abstract_t\">82</a>].</p><p>The neurologic prognosis is better for those patients without underlying cancer and for whose tumor is promptly diagnosed and treated, than for those with untreated tumors [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49\" class=\"abstract_t\">49</a>]. Older adults appear to be more likely to have relapses of symptoms and residual gait ataxia [<a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/26\" class=\"abstract_t\">26</a>].</p><p class=\"headingAnchor\" id=\"H24048008\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opsoclonus-myoclonus syndrome (OMS) is a rare syndrome, believed to have an autoimmune pathogenesis that may be paraneoplastic or non-paraneoplastic. Many non-paraneoplastic cases are believed to be para-infectious in origin.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ataxia of trunk and limbs with falling is often the first symptom. Patients subsequently develop myoclonus and opsoclonus (spontaneous, involuntary, arrhythmic, conjugate, multi-directional saccades occurring in all directions of gaze without a saccadic interval). Encephalopathy of varying severity can accompany motor symptoms. In children, a moderate to severe sleep disturbance is common. (See <a href=\"#H24048201\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All children with OMS should be evaluated for neuroblastoma. Almost 50 percent of children with OMS have an underlying neuroblastoma; symptoms of OMS precede the diagnosis of neuroblastoma in about one-half of patients. (See <a href=\"#H6266312\" class=\"local\">'Testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All adults over the age of 50 years and those with associated encephalopathy should be rigorously evaluated for occult malignancy. The most frequent tumor associated with OMS in adults is small cell lung cancer (SCLC). Breast cancer, non-small cell lung cancer, ovarian teratoma and other gynecologic cancers, and bladder tumors are also associated with OMS. (See <a href=\"#H6361463\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>OMS may respond, at least in part, to antitumor treatment <span class=\"nowrap\">and/or</span> immunosuppression. In children, however, the neurologic prognosis is guarded. Most will have long term neuropsychiatric disability regardless of pathogenesis and treatment. (See <a href=\"#H24048217\" class=\"local\">'Treatment and prognosis'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/1\" class=\"nounderline abstract_t\">Digre KB. Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 1986; 43:1165.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/2\" class=\"nounderline abstract_t\">Candler PM, Dale RC, Griffin S, et al. Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry 2006; 77:507.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/3\" class=\"nounderline abstract_t\">Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 2010; 14:156.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/4\" class=\"nounderline abstract_t\">Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005; 22:8.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/5\" class=\"nounderline abstract_t\">Hasegawa S, Matsushige T, Kajimoto M, et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev 2015; 37:656.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/6\" class=\"nounderline abstract_t\">Nussinovitch U, Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev 2012; 11:A377.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/7\" class=\"nounderline abstract_t\">Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004; 62:1526.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/8\" class=\"nounderline abstract_t\">Connolly AM, Pestronk A, Mehta S, et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997; 130:878.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/9\" class=\"nounderline abstract_t\">Blaes F, F&uuml;hlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58:313.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/10\" class=\"nounderline abstract_t\">Korfei M, F&uuml;hlhuber V, Schmidt-W&ouml;ll T, et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol 2005; 170:150.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/11\" class=\"nounderline abstract_t\">Pranzatelli MR, Tate ED, McGee NR, Ransohoff RM. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive. Cytokine 2013; 64:331.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/12\" class=\"nounderline abstract_t\">Krasenbrink I, F&uuml;hlhuber V, Juhasz-Boess I, et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatrics 2007; 38:114.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/13\" class=\"nounderline abstract_t\">Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36:612.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/14\" class=\"nounderline abstract_t\">Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22:315.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/15\" class=\"nounderline abstract_t\">Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008; 28:58.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/16\" class=\"nounderline abstract_t\">Ertekin V, Tan H. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection. Pediatr Neurol 2010; 42:441.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/17\" class=\"nounderline abstract_t\">Vukelic D, Bozinovic D, Morovic M, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect 2000; 40:189.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/18\" class=\"nounderline abstract_t\">Cardesa-Salzmann TM, Mora J, Garc&iacute;a Cazorla MA, et al. Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. Pediatr Blood Cancer 2006; 47:964.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/19\" class=\"nounderline abstract_t\">Sheth RD, Horwitz SJ, Aronoff S, et al. Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol 1995; 10:297.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/20\" class=\"nounderline abstract_t\">van Toorn R, Rabie H, Warwick JM. Opsoclonus-myoclonus in an HIV-infected child on antiretroviral therapy--possible immune reconstitution inflammatory syndrome. Eur J Paediatr Neurol 2005; 9:423.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/21\" class=\"nounderline abstract_t\">Kuban KC, Ephros MA, Freeman RL, et al. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 1983; 13:69.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/22\" class=\"nounderline abstract_t\">Huber BM, Strozzi S, Steinlin M, et al. Mycoplasma pneumoniae associated opsoclonus-myoclonus syndrome in three cases. Eur J Pediatr 2010; 169:441.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/23\" class=\"nounderline abstract_t\">Deconinck N, Scaillon M, Segers V, et al. Opsoclonus-myoclonus associated with celiac disease. Pediatr Neurol 2006; 34:312.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/24\" class=\"nounderline abstract_t\">Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005; 228:275.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/25\" class=\"nounderline abstract_t\">Wells EM, Dalmau J. Paraneoplastic neurologic disorders in children. Curr Neurol Neurosci Rep 2011; 11:187.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/26\" class=\"nounderline abstract_t\">Wong A. An update on opsoclonus. Curr Opin Neurol 2007; 20:25.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/27\" class=\"nounderline abstract_t\">Matsumura K, Sonoh M, Tamaoka A, Sakuta M. Syndrome of opsoclonus-myoclonus in hyperosmolar nonketotic coma. Ann Neurol 1985; 18:623.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/28\" class=\"nounderline abstract_t\">Desai J, Mitchell WG. Acute cerebellar ataxia, acute cerebellitis, and opsoclonus-myoclonus syndrome. J Child Neurol 2012; 27:1482.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/29\" class=\"nounderline abstract_t\">Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 2002; 27:384.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/30\" class=\"nounderline abstract_t\">Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001; 139:552.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/31\" class=\"nounderline abstract_t\">Hammer MS, Larsen MB, Stack CV. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol 1995; 13:21.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/32\" class=\"nounderline abstract_t\">Mitchell WG, Snodgrass SR. Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol 1990; 5:153.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/33\" class=\"nounderline abstract_t\">Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28:284.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/34\" class=\"nounderline abstract_t\">Pranzatelli MR, Tate ED, Kinsbourne M, et al. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG. Mov Disord 2002; 17:1387.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/35\" class=\"nounderline abstract_t\">Rost&aacute;sy K, Wilken B, Baumann M, et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatrics 2006; 37:291.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/36\" class=\"nounderline abstract_t\">Wilken B, Baumann M, Bien CG, et al. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol 2008; 12:51.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/37\" class=\"nounderline abstract_t\">Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr 2007; 166:359.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/38\" class=\"nounderline abstract_t\">Pranzatelli MR, Tate ED, Travelstead AL, et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24:316.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/39\" class=\"nounderline abstract_t\">Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008; 50:683.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/40\" class=\"nounderline abstract_t\">Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28:585.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/41\" class=\"nounderline abstract_t\">Bell J, Moran C, Blatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 2008; 50:370.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/42\" class=\"nounderline abstract_t\">Pranzatelli MR, Tate ED. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome. Pediatr Neurol 2017; 73:48.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/43\" class=\"nounderline abstract_t\">Tate ED, Pranzatelli MR, Verhulst SJ, et al. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol 2012; 27:875.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/44\" class=\"nounderline abstract_t\">De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009; 40:103.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/45\" class=\"nounderline abstract_t\">Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109:86.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/46\" class=\"nounderline abstract_t\">Krug P, Schleiermacher G, Michon J, et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14:400.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/47\" class=\"nounderline abstract_t\">Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML, et al. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer 2009; 53:1048.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/48\" class=\"nounderline abstract_t\">Pranzatelli MR, Tate ED, Dukart WS, et al. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 2005; 147:372.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/49\" class=\"nounderline abstract_t\">Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124:437.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/50\" class=\"nounderline abstract_t\">Klaas JP, Ahlskog JE, Pittock SJ, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol 2012; 69:1598.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/51\" class=\"nounderline abstract_t\">Armangu&eacute; T, Sabater L, Torres-Vega E, et al. Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol 2016; 73:417.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/52\" class=\"nounderline abstract_t\">Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53:347.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/53\" class=\"nounderline abstract_t\">Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29:241.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/54\" class=\"nounderline abstract_t\">Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996; 16:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/55\" class=\"nounderline abstract_t\">Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53:580.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/56\" class=\"nounderline abstract_t\">Fitzpatrick AS, Gray OM, McConville J, McDonnell GV. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology 2008; 70:1292.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/57\" class=\"nounderline abstract_t\">Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol 2006; 253:942.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/58\" class=\"nounderline abstract_t\">Kawachi I, Saji E, Toyoshima Y, et al. Treatment responsive opsoclonus-ataxia associated with ovarian teratoma. J Neurol Neurosurg Psychiatry 2010; 81:581.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/59\" class=\"nounderline abstract_t\">Erlich R, Morrison C, Kim B, et al. ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response. Cancer Invest 2004; 22:257.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/60\" class=\"nounderline abstract_t\">Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993; 43:207.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/61\" class=\"nounderline abstract_t\">Lewis MA, Hartmann LC, Lachance DH, Jimenez RE. Opsoclonus as a suspected paraneoplastic syndrome of endometrial cancer. Rare Tumors 2010; 2:e42.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/62\" class=\"nounderline abstract_t\">Weizman DA, Leong WL. Anti-Ri antibody opsoclonus-myoclonus syndrome and breast cancer: a case report and a review of the literature. J Surg Oncol 2004; 87:143.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/63\" class=\"nounderline abstract_t\">Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci U S A 1998; 95:13254.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/64\" class=\"nounderline abstract_t\">DeFelipe-Mimbrera A, Masjuan J, Corral &Iacute;, et al. Opsoclonus-myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF. J Neuroimmunol 2014; 272:91.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/65\" class=\"nounderline abstract_t\">Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13:276.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/66\" class=\"nounderline abstract_t\">Peter L, Jung J, Tilikete C, et al. Opsoclonus-myoclonus as a manifestation of Lyme disease. J Neurol Neurosurg Psychiatry 2006; 77:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/67\" class=\"nounderline abstract_t\">Wiest G, Safoschnik G, Schnaberth G, Mueller C. Ocular flutter and truncal ataxia may be associated with enterovirus infection. J Neurol 1997; 244:288.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/68\" class=\"nounderline abstract_t\">Alshekhlee A, Sultan B, Chandar K. Opsoclonus persisting during sleep in West Nile encephalitis. Arch Neurol 2006; 63:1324.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/69\" class=\"nounderline abstract_t\">Verma A, Brozman B. Opsoclonus-myoclonus syndrome following Epstein-Barr virus infection. Neurology 2002; 58:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/70\" class=\"nounderline abstract_t\">Kanjanasut N, Phanthumchinda K, Bhidayasiri R. HIV-related opsoclonus-myoclonus-ataxia syndrome: report on two cases. Clin Neurol Neurosurg 2010; 112:572.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/71\" class=\"nounderline abstract_t\">Scott KM, Parker F, Heckmann JM. Opsoclonus-myoclonus syndrome and HIV-infection. J Neurol Sci 2009; 284:192.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/72\" class=\"nounderline abstract_t\">Ayarza A, Parisi V, Altclas J, et al. Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion. J Neurol 2009; 256:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/73\" class=\"nounderline abstract_t\">Flabeau O, Meissner W, Foubert-Samier A, et al. Opsoclonus myoclonus syndrome in the context of Salmonellosis. Mov Disord 2009; 24:2306.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/74\" class=\"nounderline abstract_t\">Zaganas I, Prinianakis G, Xirouchaki N, Mavridis M. Opsoclonus-myoclonus syndrome associated with cytomegalovirus encephalitis. Neurology 2007; 68:1636.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/75\" class=\"nounderline abstract_t\">Lapenna F, Lochi L, de Mari M, et al. Post-vaccinic opsoclonus-myoclonus syndrome: a case report. Parkinsonism Relat Disord 2000; 6:241.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/76\" class=\"nounderline abstract_t\">Dassan P, Clarke C, Sharp DJ. A case of poststreptococcal opsoclonus-myoclonus syndrome. Mov Disord 2007; 22:1490.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/77\" class=\"nounderline abstract_t\">Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) 1988; 67:100.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/78\" class=\"nounderline abstract_t\">Hormigo A, Dalmau J, Rosenblum MK, et al. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol 1994; 36:896.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/79\" class=\"nounderline abstract_t\">Armangue T, Titulaer MJ, Sabater L, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 2014; 75:435.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/80\" class=\"nounderline abstract_t\">Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/81\" class=\"nounderline abstract_t\">Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol 2006; 56:240.</a></li><li><a href=\"https://www.uptodate.com/contents/opsoclonus-myoclonus-syndrome/abstract/82\" class=\"nounderline abstract_t\">Fernandes TD, Bazan R, Betting LE, da Rocha FC. Topiramate effect in opsoclonus-myoclonus-ataxia syndrome. Arch Neurol 2012; 69:133.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15861 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24048008\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H24048016\" id=\"outline-link-H24048016\">INTRODUCTION</a></li><li><a href=\"#H24047689\" id=\"outline-link-H24047689\">PEDIATRIC SYNDROME</a><ul><li><a href=\"#H24048187\" id=\"outline-link-H24048187\">Pathogenesis</a></li><li><a href=\"#H24048201\" id=\"outline-link-H24048201\">Clinical features</a></li><li><a href=\"#H24048209\" id=\"outline-link-H24048209\">Evaluation</a><ul><li><a href=\"#H6266249\" id=\"outline-link-H6266249\">- Differential diagnosis</a></li><li><a href=\"#H6266312\" id=\"outline-link-H6266312\">- Testing</a></li></ul></li><li><a href=\"#H24048217\" id=\"outline-link-H24048217\">Treatment and prognosis</a></li></ul></li><li><a href=\"#H24047696\" id=\"outline-link-H24047696\">ADULT SYNDROME</a><ul><li><a href=\"#H6361449\" id=\"outline-link-H6361449\">Pathogenesis</a></li><li><a href=\"#H6361456\" id=\"outline-link-H6361456\">Clinical features</a></li><li><a href=\"#H6361463\" id=\"outline-link-H6361463\">Diagnosis</a></li><li><a href=\"#H6361600\" id=\"outline-link-H6361600\">Treatment and prognosis</a></li></ul></li><li><a href=\"#H24048008\" id=\"outline-link-H24048008\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-cerebellar-ataxia-in-children\" class=\"medical medical_review\">Acute cerebellar ataxia in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-toxic-metabolic-encephalopathy-in-adults\" class=\"medical medical_review\">Acute toxic-metabolic encephalopathy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-toxic-metabolic-encephalopathy-in-children\" class=\"medical medical_review\">Acute toxic-metabolic encephalopathy in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-and-evaluation-of-myoclonus\" class=\"medical medical_review\">Classification and evaluation of myoclonus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-diagnosis-and-staging-evaluation-of-neuroblastoma\" class=\"medical medical_review\">Clinical presentation, diagnosis, and staging evaluation of neuroblastoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-neuroblastoma\" class=\"medical medical_review\">Epidemiology, pathogenesis, and pathology of neuroblastoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-paraneoplastic-syndromes-of-the-nervous-system\" class=\"medical medical_review\">Overview of paraneoplastic syndromes of the nervous system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-peripheral-nerve-and-muscle\" class=\"medical medical_review\">Paraneoplastic syndromes affecting peripheral nerve and muscle</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-syndromes-affecting-the-spinal-cord-and-dorsal-root-ganglia\" class=\"medical medical_review\">Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=symptomatic-secondary-myoclonus\" class=\"medical medical_review\">Symptomatic (secondary) myoclonus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-neuroblastoma\" class=\"medical medical_review\">Treatment and prognosis of neuroblastoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-myoclonus\" class=\"medical medical_review\">Treatment of myoclonus</a></li></ul></div></div>","javascript":null}